Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Weipixiao attenuate early angiogenesis in rats with gastric precancerous lesions

BMC Complementary and Alternative Medicine201818:250

https://doi.org/10.1186/s12906-018-2309-3

  • Received: 7 September 2017
  • Accepted: 12 February 2018
  • Published:
Open Peer Review reports

Abstract

Background

Angiogenesis is a pathobiological hallmark of gastric cancer. However, rare studies focus on angiogenesis in gastric precancerous lesions (GPL). Weipixiao (WPX), a Chinese herbal preparation, is proved clinically effective in treating GPL. Here, we evaluated WPX’s anti-angiogenic potential for GPL, and also investigated the possibility of its anti-angiogenic mechanisms.

Methods

HPLC analysis was applied to screen the major chemical components of WPX. After modeling N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)-induced GPL in male Sprague-Dawley rats, different doses of WPX were administrated orally for 10 weeks. Next, we performed histopathological examination using routine H&E staining and HID-AB-PAS staining. In parallel, we assessed angiogenesis revealed by microvessel density (MVD) using CD34 immunostaining, and subsequently observe microvessel ultrastructure in gastric mucosa under Transmission Electron Microscope. Finally, we detect expression of angiogenesis-associated markers VEGF and HIF-1α using immunohistochemistry. Moreover, mRNA expressions of ERK1, ERK2, Cylin D1 as well as HIF-1α in gastric mucosa were determined by quantitative real-time reverse transcription- polymerase chain reaction.

Results

We observed the appearance of active angiogenesis in GPL rats, and demonstrated that WPX could reduce microvascular abnormalities and attenuate early angiogenesis in most of GPL specimens with a concomitant regression of most intestinal metaplasia (IM) and a portion of gastric epithelial dysplasia (GED). In parallel, WPX could suppress HIF-1α mRNA expression (P < 0.01) as well as protein expression (although without statistical significance), and could markedly inhibit VEGF protein expression in GPL rats. Mechanistically, WPX intervention, especially at low dose, caused a significant decrease in the ERK1 and Cylin D1 mRNA levels. However, WPX might probably have no regulatory effect on ERK2 amplification.

Conclusions

WPX could attenuate early angiogenesis and temper microvascular abnormalities in GPL rats. This might be partly achieved by inhibiting on the angiogenesis-associated markers HIF-1α and VEGF, and on the ERK1/Cylin D1 aberrant activation.

Keywords

  • Gastric precancerous lesions
  • ERK signaling
  • VEGF
  • HIF-1α
  • Herbal medicine
  • Weipixiao

Background

Gastric precancerous lesions (GPL) are generally defined as intestinal metaplasia (IM) and gastric epithelial dysplasia (GED). A direct link has been sought between gastric cancer and high prevalence of GPL worldwide [13], especially in Asia. Thus, blocking of gastric precancerosis toward malignant transformation is crucial to reducing the gastric cancer incidence. Nowadays, endoscopic mucosal resection is clinically applied only to severe GED and definite intramucosal carcinoma, yet most cases of GPL are not amenable to the endoscopic resection [4]. Moreover, vitacoenzyme tablet, a chemopreventive agent used in China, has been reported to be beneficial in treating atrophic gastritis and metaplasia lesion [5, 6]. Its therapeutic effect against GPL, however, was not completely confirmed. Therefore, the pursuit to discover alternative therapies to treat GPL is of high concern. In China, early herbal intervention has proved to be effective in halting and even reversing the majority of GPL [7, 8].

Angiogenesis, the sprouting of new capillaries from pre-existing vessels, is a fundamental process accelerating gastric cancer progression. Considerable evidence has demonstrated that excessive angiogenesis is significantly correlated with enhanced migratory and invasive activity, and therefore with poor prognosis [911]. Hence, targeting angiogenesis has been a central focus in gastric cancer treatment [12]. Angiogenesis is generally resulted from hypoxia orchestrated by multiple transcriptional activators, aiming at restoring intratumoral O2 delivery to hypoxic regions, thereby sustaining tumor growth [13]. Hypoxia inducible factor-1α (HIF-1α) has been proved to be a key regulator of cellular adaptation to hypoxia involved in angiogenesis process, and the process is frequently accompanied by a concomitant aberrant activation of vascular endothelial growth factor (VEGF) [14], which is essential for vascular development and can induce proliferation, differentiation and apoptosis of endothelial cells. Extracellular signal-regulated kinase (ERK), which may serve as specific effectors of VEGF signaling, play a vital role in sprouting endothelial cells during vascular development [15]. Aberrant activation of ERK signaling is closely linked to the carcinogenesis and development of gastric cancer [16]. ERK1 has been reported to overexpressed in 52.98% (231/436) cases of human gastric tumor, and high level of ERK1 protein expression was significantly correlated with age, tumor location, depth of invasion, Lauren’s classification, lymph node metastasis and tumor node metastasis (TNM) stage [17]. ERK2 is similarly important for predicting the prognosis of gastric cancer. The positive occurrence of ERK2 mRNA expression is 64.0% (32/50) in tumor tissues from patients with gastric cancer, which is markedly higher than that in non-cancerous tissues showing 18.0% (9/50) [18]. Furthermore, ERK2 expression level is significantly increased from TNM stage II to stage IV, suggesting a closely relationship between elevated ERK2 level and tumor invasion and TNM stage [18]. Cyclin D1 is involved in G1-S point of cell cycle, and thus induces cell proliferation and migration coexisted with angiogenesis. Cyclin D1 is frequently over-expressed in a substantial proportion of gastric cancer, and its expression may be governed by the ERK signaling [19, 20]. Although studies reported in recent years have addressed the pro-angiogenic role of the molecules in gastric cancer, it is unclear what role the molecules may play in gastric precancerosis.

Weipixiao (WPX) is a Chinese herbal prescription consisting of six herbs including Astragalus Membranaceus, Pseudostellaria Heterophylla, Atractylodis Macrocephalae, Curcuma zedoaria, Salvia Miltiorrhiza and Hedyotis Diffusa Willd. WPX prescription has been widely used in clinical for more than 15 years, and it shows satisfactory effects against “non-progressive GPL”. In previous clinical trials, different teams demonstrated that WPX possesses excellent abilities at relieving the clinical symptoms, reducing the precursor lesions (through gastroscopic and pathohistological examination), as well as partially eradicating Helicobacter pylori in GPL patients, and shows no toxic or side effects [2123]. Experimentally, some WPX individuals exhibited potential anti-angiogenesis activities in several solid tumors. Extracts from Astragalus membranaceus, a “Yi Qi Hua Yu” herb (function to tonify qi and activate blood) belonging to WPX, could reduce angiogenesis-related molecules vascular endothelial growth factor and cyclooxygenase-2 in ovarian tumor-bearing mice [24]. Another active compound of Astragalus membranaceus, named formononetin, has been reported to repress hypoxia-induced retinal angiogenesis via the HIF-1α/VEGF signaling pathway [25]. Essential oil from another member Curcuma zedoaria, a widely used “Hua Yu Tong Luo” herb (function to dissipate blood stasis and free the collateral vessels), presented the anti-angiogenic activity, which therefore contributed to suppressing melanoma growth and lung metastasis [26]. A recent study suggested that Danshensu, a major water-soluble compound from Salvia miltiorrhiza, could improve microcirculation and remodel tumor vasculature, thereby enhancing the radioresponse for Lewis lung carcinoma xenografts in mice [27]. The aforementioned researchers revealed the anti-angiogenesis properties of several herbs from WPX. However, the anti-angiogenic potential of WPX in GPL treating, and the possibility of its anti-angiogenic mechanisms still remain unclear.

In this study, we tested whether early angiogenesis existed in N-methyl-N′-nitro-N-nitrosoguanidine (MNNG)-induced GPL rats. Also, we determined whether WPX had the ability against hyper- angiogenesis. In parallel, we screened potential anti-GPL constituents of WPX. More importantly, the hypothesis we wished to test was that the anti-angiogenesis property of WPX was associated with its regulatory effects on the angiogenesis-associated markers HIF-1α and VEGF, and on the ERK/Cylin D1 signal transduction pathway.

Methods

Animals

Male Sprague-Dawley rats weighting 150–170 g were obtained from Experimental Animal Center of Sun Yat-sen University (certificate No. 0111909). Animals were housed in a specific pathogen-free animal room, kept under optimal condition at 23 ± 1 °C and 40–60% humidity with a 12 h light-dark cycle, and fed with standard rat chow. All procedures relating to animal care and the animal research protocols conformed to the guidelines for the Care and Use of Laboratory Animal, issued by the Ministry of Science and Technology of China. This experiment was conducted in Guangdong Provincial Institute of Traditional Chinese Medicine, and was presented to the institutional ethical review board for approval (Ethic No. GDPITCM111018).

Drugs and reagents

WPX comprises the following components: Huangqi (Astragalus Membranaceus)30 g, Taizishen (Pseudostellaria Heterophylla)15 g, Baishu (Atractylodis Macrocephalae)15 g, Eshu (Curcuma zedoaria)10 g, Danshen (Salvia Miltiorrhiza)10 g and Baihuasheshecao (Hedyotis Diffusa Willd)30 g. The herbs were provided and authenticated by the First Affiliated Hosipital of Guangzhou University of Chinese Medicine. The medical herbs were boiled with distilled water, and concentrated into a mixture containing crude drugs 1.5 g/mL. MNNG was supplied by Tokyo Kabushiki Kaisha, Japan (No. ZG4T1-FP). CD34 antibody was abtained from R&D Systems, USA (lot ZDP0112111); VEGF antibody was supplied by Abcam, UK (lot GR-116031-1); HIF-1α antibody was purchased from Santa Cruz Biotechnology, USA (lot L1212). Maxima™ SYBR Green/Fluorescein qPCR Master Mix (2X) was supplied by Fermentas, USA.

High performance liquid chromatography (HPLC) analysis

HPLC analysis was performed to screen the potential chemical constituents of WPX preparation. Condition optimization of fingerprint: JADE-PAK ODS-AQ column (250 × 4.6 mm, 5 μm) and Inertsil ODS-SP column (4.6 × 150 mm, 5 μm) were utilized, with acetonitrile 0.1% phosphoric acid solution and acetonitrile 0.4% phosphoric acid solution as the mobile phase respectively, under full wavelength detection. The following chromatographic analysis conditions were determined: the separation was determined on Inertsil ODS-SP column (4.6 × 150 mm, 5 μm) with a mobile phase of acetonitrile (solvent A) 0.4% phosphoric acid solution (solvent B). For HPLC analysis, a 10 μL sample was injected into the column and eluted at a flow rate of 1.0 ml/min under room temperature. The detective wavelength was 203 nm.

Grouping, modeling and treatment

SD rats were randomly divided into six experimental groups: control group (n = 9), model group (n = 11), model + vitacoenzyme group (VIT, n = 9, 0.2 g/kg/d), model + high-dose WPX group (H-WPX, n = 9, 15 g/kg/d), model + medium-dose WPX group (M-WPX, n = 9, 7.5 g/kg/d), and model + low-dose WPX group (L-WPX, n = 9, 3.75 g/kg/d). Based on the literatures [8, 28, 29], the GPL rat model was set up with minor modifications. Briefly, All the rats, except for control rats, were allowed to drink MNNG solution (200 μg·ml− 1) ad libitum, and underwent hunger-satiety shift every other day. At the end of 15th week, 2 random rats in the model group were humanely terminated with sodium pentobarbital (140 mg/kg i.p.) and examined for IM/GED. At the beginning of 16th week, the treated rats were administered WPX or VIT by gastrogavage for 10 consecutive weeks, while the control and the model rats were given 2 mL distilled water by gastrogavage once daily.

Pathological examination

Animals were humanely euthanized with sodium pentobarbital (140 mg/kg i.p.) after 12 h fasting, and the stomachs were removed immediately, incised along the greater curvature, and fixed in 10% neutralized formalin solution. Then, each sample was embedded in paraffin wax and serially sectioned at 3 μm thick. The sections were stained with hematoxylin and eosin (H-E staining), and with high-iron diamine-alcian blue-periodic acid Schiff (HID-AB-PAS staining). Gastric tissues were examined macroscopically to identify IM and GED lesions in rats.

Evaluation of microvessel density

To evaluate microvessel density (MVD) in gastric mucosa, CD34 expression was determined using EnVision immunohistochemistry. Quantification of MVD was specified by Weidner et al. [30]. Briefly, area of highest angiogenesis (also called hot-spot) were identified under low-power magnification (40× and 100×), and stained microvessels in three random views of the ‘hot-spot’ area were counted under high-power magnification (200×). The mean value of the three 200× field counts was recorded as MVD for each case. Any brown staining endothelial cell or cell cluster that was clearly separated from adjacent microvessels or other connective tissue was considered a single countable microvessel.

Microvessel ultrastructure

The gastric mucosa tissue were sliced into 1 mm3 pieces and fixed with 2.5% glutaraldehyde in phosphate buffer for 2.5 h, and then re-fixed in 1% osmium tetroxide in phosphate buffer for 2 h. The tissues were dehydrated in a graded series of ethanol solutions and then immersion in a mixture of acetone and epoxy resin twice (2:1 for 3 h in the first time, 1:2 for overnight in the second time). Finally, the tissues were embedded in epoxy resin-filled capsules and heated at 70 °C overnight, ultrathin sections (60–80 nm) were sliced with LKB microtome. The sections were viewed and photographed under a transmission electron microscope (JEOL 100C, JEOL, Tokyo, Japan).

Levels of ERK1, ERK2, Cyclin D1 and HIF-1α by RT-qPCR

The mRNA levels of ERK1, ERK2, Cyclin D1 and HIF-1α were determined by quantitative real-time reverse transcription-polymerase chain reaction (RT-qPCR) method using Maxima™ SYBR Green/Fluorescein qPCR Master Mix (Fermentas, USA) via IQ™5 real-time PCR detection system (Bio-Rad, USA). The PCR primers used were as follows: ERK1 (GenBank accession no. NM_011952; 104 bp) forward, 5′-CGGATTGCTGACCCT-3′ and reverse 5′-GTGTAGCCCTTGGAGTT-3′; ERK2 (GenBank accession no. NM_053842; 113 bp) forward, 5′-CAACCTCCTGCTGAAC-3′ and reverse 5′-GCGTGGCTACATACTC-3′; Cyclin D1 (GenBank accession no. NM_171992; 191 bp) forward, 5′-GCAGAAGTGCGAAGAGG-3′ and reverse 5′-GGCGGATAGAGTTGTCAGT-3′; HIF-1α (GenBank accession no. NM_024359; 132 bp) forward, 5′-CAACTGCCACCACTGATG-3′ and reverse 5′-CACTGTATGCTGATGCCTTAG-3′; 18S (GenBank accession no. M11188; 204 bp) forward, 5′-TCAGCCACCCGAGATT-3′ and reverse 5′-GCTTATGACCCGCACTTA-3′. The level of 18 s mRNA transcript was used to normalize all reported gene expression levels, and the data were analyzed using 2-Ct method.

Expression of VEGF and HIF-1α by immunohistochemistry

Formalinfixed and paraffin-embedded gastric tissues were cut at 3 μm thick. The EnVision immunohistochemical technology was utilized, VEGF protein immunoreactivity was shown as brown color in the cytosolic and perinuclear regions of gastric epithelial cells. HIF-1α positive staining was brown or brown yellow and was detected predominantly in the cytoplasm and nucleus. To access the protein expression levels of VEGF and HIF-1α, three visual fields were randomly selected from each slice under light microscope (100×), and then images were acquired and analyzed by Image Pro Plus 6.0 software. Quantification of VEGF and HIF-1α levels was determined using mean of integrated optical density (IOD).

Statistical analysis

Data were presented as mean ± standard deviation (SD). Statistical analysis was performed using IBM SPSS 19.0 software (SPSS, Chicago, IL). One-way analysis of variance (ANOVA) was applied to analyze the comparisons among multiple groups. The comparison between two groups was performed with SNK method for the homogeneous variances, while the variances were heterogeneous, Dunnett’s T3 method should be adopted. A P value of less than 0.05 was considered as significant.

Results

HPLC profile

WPX possessed an excellent ability against GPL revealed by our previous clinical trials and animal testing, so we are curious about the major constituents of WPX polyherbal mixture. Figure 1 shows the HPLC chromatograms of WPX test sample (A) and reference sample (B). The retention times of the major chemical constituents were 20.5 min (Calycosin-7- glucoside), 34.8 min (ginsenoside-Rg1), 48.3 min (ginsenoside-Rb1), 49.5 min (astragaloside IV), 59.0 min (atractylenolide III), 71.7 min (atractylenolide II), and 81.7 min (atractylenolide I) (Fig. 1).
Fig. 1
Fig. 1

HPLC chromatogram of WPX test sample (a) and reference sample (b). Notes: Peak: 1, Calycosin-7-glucoside; 2, ginsenoside-Rg1; 3, ginsenoside-Rb1; 4, astragaloside IV; 5–7, atractylenolide III, II, and I, respectively

WPX efficiently blocked and even reversed gastric intestinal metaplasia

We evaluated the degree of IM lesion in gastric tissues by HID-AB-PAS staining. As depicted in Fig. 2, neutral mucins present in normal mucosa were stained red, gastric specimens from controls didn’t exhibit IM lesion. In model rats, sialomucins expressed only in small intestinal-type metaplasia (S-IM) were stained blue, and sulfomucins present in colonic-type metaplasia (C-IM) were stained brown, indicating that both S-IM and C-IM were widespread. In treated rats, IM lesion was regressed slightly in VIT-treated rats. Comparatively, IM lesion was regressed visibly in WPX-treated rats. Our observation revealed that WPX has a potent anti-IM capacity in GPL rats (Fig. 2).
Fig. 2
Fig. 2

Histological evaluation of gastric intestinal metaplasia. Neutral mucins present in normal mucosa were stained red. Sialomucins expressed only in small intestinal-type metaplasia (S-IM) were stained blue, and sulfomucins present in colonic-type metaplasia (C-IM) were stained brown. Images of model gastric epithelium depicted prominent S-IM and C-IM lesions, which were dramatically reduced after WPX administration. n = 9 in each group. (HID-AB-PAS staining, 100×)

WPX partly ameliorated gastric epithelial dysplasia

To further investigate the anti-GPL effect of WPX, we also examined the GED lesion in H&E stained sections of gastric tissues. Histologically, the control gland and cell structure of gastric epithelium remained intact. By contrast, almost all model rats displayed GED pathology. In detail, gastric epithelium was characterized by architectural abnormalities showing splitting, elongated, crowded glands and back-to-back tubular structure, and also by cytological atypia with hyperchromatic nuclei, increased nuclear-cytoplasmic ratio, loss of nuclear polarity and occasional binucleation. Inflammatory infiltration was variable, and sometimes extensive. Occasionally, two model rats exhibited mild dysplasia, due to the multifocal nature of the dysplastic lesion. In most cases of WPX-treated rats, GED lesion alterations, especially tubular structure irregularities and inflammatory infiltration, were regressed in varying degrees. However, the treatment was not able to restore the GED pathology near to the normal tissues. In contrast, this GED-rescuing effect was not presented in most VIT-treated rats. These observations suggested that WPX could partly halt and even reverse dysplastic process, especially the “non-progressive GED” (Fig. 3).
Fig. 3
Fig. 3

Histological evaluation of gastric epithelial dysplasia. Model gastric epithelium displayed GED pathology characterized by glandular architectural abnormalities such as splitting, elongated and crowded glands, back to back formation, as well as by cytological atypia with rounded, pleomorphic nuclei that display prominent nucleoli and loss of polarity. After WPX intervention, these GED pathological alterations, especially irregularities of glandular structure, were regressed in varying degrees. n = 9 in each group. (H&E staining, 100×)

WPX reduced the CD34+ MVD level in GPL tissues

In order to identify whether early angiogenesis occur in GPL, we examined the angiogenic state in gastric tissues using CD34-labelled sections. As visualized by light microscopy, an increased number of CD34+ microvessels, which were suggestive of active angiogenesis, could be found in most cases of GPL tissues, whereas those in control tissues were minimal. Moreover, we found more GEDs with a higher number of microvessels than IMs, and more severe GEDs than mild or moderate GEDs. Occasionally, CD34+ microvessels were apparently abundant and distributed diffusely in two model rats all diagnosed with severe GED. By contrast, we observed a clear decreased CD34+ microvessel count in many cases of WPX-treated rats. Our data showed a statistic significant increase of CD34+ MVD level in model rats comparing to controls. But it dropped by at least half after WPX intervention, when in comparison to the non-treatment rats. Thus, WPX could effectively inhibit active angiogenesis in GPL rats (Fig. 4).
Fig. 4
Fig. 4

Evaluation of CD34-labelled microvessel density in gastric mucosa. a CD34-labelled microvessels in gastric mucosa from various groups. Some representative microvessels are indicated by black arrows. b Scores of CD34+ MVD levels. The results are expressed as mean ± SD (n = 9 in each group). Note: ##P < 0.01, vs Control; **P < 0.01, vs Model; P < 0.05, vs VIT. (IHC, 200×)

WPX tempered microvascular abnormalities in GPL tissues

We further examined the morphological changes of microvessels in gastric mucosa under transmission electron microscope. In control rats, microvessels were clearly demarcated from the surrounding connective tissues. The microvessels appeared a normal vascular inner diameter, smooth basal lamina with uniform thickness, and also showed a complete and clear structure of basal lamina with homogeneous electron-density. Endothelial cell bordering the basal lamina was morphologically flat or elongated, with smooth and clear nuclear membrane and normal chromatin distribution.

In model rats, intervascular boundaries were ill-defined or invisible. Remodeled microvessels showed dilated vascular lumen but with a markedly decreased inner diameter, accompanied with clearly thickened, rough basal lamina which was often coated by abundant high-density granules aggregation. Some vascular lumens were partly or completely occluded by erythrocytes and neutrophils. Apart from these, features such as segmental breakup of basal lumina and increased vascular permeability also existed. Furthermore, endothelial cells displayed severe swelling and were shaped like grapes, with debased cytoplasm electron-density, nucleus chromatin condensation, as well as abundant pinocytotic vesicles. Abnormalitiesof vascular lumen, basal lamina and endothelial cell were still prominent in VIT-treated rats.

In WPX-treated rats, vascular lumen showed a mild-moderate decrease in inner diameter. Basal lamina coated by some high-density granule aggregation was still a little rough, and also with occasional breakup. Endothelial cells exhibited slight swelling and mild vacuolisation. Most of the nuclear membrane became clear and complete, and nucleus chromatin distribution also became normalized. Accordingly, WPX intervention could normalize ultrastructural alterations of vascular lumen, basal lamina and endothelial cell, thus showing the potent rescuing effect of WPX on microvascular abnormalities in GPL rats (Fig. 5).
Fig. 5
Fig. 5

Representative electron micrographs of microvessels in gastric mucosa. Control group: TEM observation of control microvessel ultrastructures appeared intact, in terms of vascular lumen, basal lamina and endothelial cell. Model group: Microvessels lost their typical structures. Vascular lumen, frequently plugged by erythrocytes, was dilated but with a markedly decreased inner diameter. Clearly thickened, rough basal lamina was coated by abundant high-density granules aggregation. Segmental breakup of basal lumina and increased vascular permeability were also existed. Endothelial cells were conglobated and shaped as grapes, characterized by debased cytoplasm electron-density, nucleus chromatin condensation, as well as numerous pinocytotic vesicles. Treatment group: Microvascular abnormalities were still prominent in VIT-treated tissues. However, the abnormalities reversed markedly in WPX-treated tissues, especially in terms of vascular lumen and basal lamina. Even in a few cases, the microvessels were detected to ultrastructurally resemble the normal ones. Note: Opposing arrows mark the thickness of basal lamina; EC, endothelial cell; BL, basal lamina; Lu, lumen; RBC, red blood cell. n = 9 in each group. (10000×)

Effect of WPX on HIF-1α mRNA levels

HIF-1α plays an important role in hypoxic responses and induces the transcription of various genes responsible for tumor angiogenesis, invasion and metastasis. Thus, we texted whether WPX possessed a regulatory ability on hypoxic responses in GPL rats through classic HIF-1α marker detection. Figure 6 clearly showed that HIF-1α mRNA level was elevated in GPL rats when compared with those of controls (although without statistical significance). Compared with model rats, HIF-1α mRNA levels in rats were significantly diminished by medium and low doses of WPX. By comparison, treatment with low dose of WPX led to a marked reduction in HIF-1α mRNA level. The data suggest that WPX, especially at low dose, could efficiently inhibit HIF-1α mRNA expression in GPL rats (Fig. 6).
Fig. 6
Fig. 6

Effect of WPX on HIF-1α mRNA levels in gastric epithelial cells. The results are expressed as mean ± SD (n = 9 in each group). Note: **P < 0.01, *P < 0.05, vs Model; ▲▲P < 0.01, vs VIT; P < 0.01, vs H-WPX

Effect of WPX on HIF-1α protein expressions

We subsequently applied immunohistochemistry to visualize activation of presumptive HIF-1α marker in gastric mucosa. By immunostaining, HIF-1α was sparsely expressed in normal gastric mucosa, whereas HIF-1α positive cells were found relatively abundant in most GPL tissues. Moreover, we found that WPX could visually reduce the number of HIF-1α positive cells in majority of GPL tissues, as shown in Fig. 7a. Semiquantitatively, elevated HIF-1α protein expression was observed in GPL mucosa as compared to normal mucosa. After WPX intervention, we found a clearly downtrend, although without statistical significance, of HIF-1α levels in gastric mucosa. Our results indicated that WPX treatment may produce regulatory effects on hypoxic responses in GPL gastric mucosa (Fig. 7).
Fig. 7
Fig. 7

Effect of WPX on HIF-1α protein expressions in gastric epithelium. a HIF-1α protein expressions in gastric epithelium from different groups. b IOD scores of HIF-1α protein levels. The results are expressed as mean ± SD (n = 9 in each group). Note: ##P < 0.01, vs Control. (IHC, 100×)

Effect of WPX on VEGF protein expressions

VEGF is generally considered as a vital driving force behind the angiogenesis process, thus we next tested whether VEGF inhibition was of relevance for WPX’s anti-angiogenic capacity. As shown in Fig. 8a, normal gastric mucosa did not or barely express VEGF marker, while diffuse and intense cytoplasmic labeling, found in most cases of GPL rats, could be markedly diminished by WPX. Statistically, GPL rats displayed an increased VEGF protein expression compared with negative controls, whereas WPX treatment reduced the over-expression. In addition, we observed a stronger inhibition effect of L-WPX on VEGF over-expression than that of VIT treatment. Intriguingly, we found HIF-1α and VEGF reduction was frequently along with the attenuation of CD34+ angiogenesis in GPL tissues, indicating that HIF-1α and VEGF inhibition may play a beneficial role in WPX-alleviated angiogenesis (Fig. 8).
Fig. 8
Fig. 8

Effect of WPX on VEGF protein expressions in gastric epithelium. a VEGF protein expressions in gastric epithelium in various groups. b IOD scores of HIF-1α protein levels. The results are expressed as mean ± SD (n = 9 in each group). Note: ##P < 0.01, vs Control; **P < 0.01, *P < 0.05, vs Model; ▲▲P < 0.01, vs VIT. (IHC, 100×)

Effect of WPX on ERK1, ERK2 and Cyclin D1 mRNA levels

To identify the possible mechanism underlying the anti-angiogenesis activity of WPX on GPL rats, we examined the key targets ERK1, ERK2 and Cyclin D1, which are closely related to the HIF-1α and EVGF signals. As described above, ERK is a specific effector of VEGF signaling and plays a pro-angiogenic role in sprouting [12], thereby instrumental in the progression of gastric cancer. As shown in Fig. 9, we found the gastric precancerous tissues with dramatically elevated ERK1 mRNA levels, which could be reversed by varying concentrations of WPXs. In addition, low dose WPX was found to be markedly superior to VIT in reducing mucosal ERK1 levels. We also noted an elevated ERK2 mRNA levels in GPL tissues, when in comparison to normal gastric tissues. However, in most cases of WPX-treated rats, upregulated ERK2 mRNA levels remained.
Fig. 9
Fig. 9

Effect of WPX on the mRNA levels of ERK1, ERK2 and Cyclin D1 in gastric epithelial cells. a ERK1 mRNA levels of gastric epithelium in various groups. b ERK2 mRNA levels of gastric epithelium in various groups. c Cyclin D1 mRNA levels of gastric epithelium in various groups. The results are expressed as mean ± SD (n = 9 in each group). Note: ##P < 0.01, vs Control; **P < 0.01, **P < 0.05, vs Model; P < 0.05, vs VIT; P < 0.05, vs H-WPX

We then analyzed mRNA levels of Cyclin D1, a downstream molecule related to ERK signals. Real-time PCR results revealed that GPL rats exhibited notably elevated Cyclin D1 levels compared with the controls. Importantly, WPX treatment caused a marked drop of Cyclin D1 levels in GPL tissues. Similar to ERK1, the inhibitory activity on Cyclin D1 by WPX was more distinct at low dose. Taken together, our findings implicated that the anti-angiogenesis effect of WPX was achieved partly by suppressing ERK1 and Cyclin D1 activation, and its inhibitory effect was identified to be more potent than that of VIT. However, WPX may have little effect on ERK2 amplification (Fig. 9).

Discussion

It is well established that gastric carcinogenesis is a complex and multifactorial process, in which accumulation of multiple genetic changes may be implicated. The recognized human model [31] of gastric carcinogenesis comprises the following precancerous steps: superficial gastritis → multifocal atrophic gastritis → intestinal metaplasia → dysplasia. Based on differences in the magnitude of the malignant risk, GPL could be categorized into (1) “non-progressive GPL” (mainly contains S-IM, mild and moderate dysplasia), remaining a comparatively stable status and with a reduced risk of evolving into gastric carcinoma [32, 33], and (2) “progressive GPL” (comprises some cases of C-IM and severe dysplasia), which is more ominous due to a relatively high risk of malignant transformation and requires advisably interval endoscopic and histologic controls [34, 35]. The vast majority of GPL represents a stage within a prolonged process and remains stable, thereby providing an opportunity to block and even reverse the precursors. WPX is a typical Chinese herbal prescription proved clinically effective in treating GPL.

In this project, almost all model rats exhibited GPL pathology, which ranged from moderate IM to severe GED lesion. After WPX administration, IM lesion (including S-IM and C-IM) were markedly regressed in most cases of GPL rats. We also found that WPX could halt and even reverse the majority of mild and moderate dysplasia. However, 4 WPX-treated rats (two M-WPX rats, one H-WPX rat, one L-WPX rat) displayed moderate or severe GED pathology, suggesting that a refractory state to WPX administration might have developed in a certain percentage of “progressive GPL”. Our observations reinforce the view that a few advanced GED and early gastric cancer are partly similar, in terms of cell proliferative activity and cell atypia. Thus, some cases of “progressive GPL” might be difficult to block and reverse.

Microvasculature serves to circulate and transport oxygen and nutrients, which is imperative to various tissues including gastric mucosa. In contrast to the normal microvasculature, cancer-related angiogenesis, which is continually activated and unregulated [36], is a fundamental pathobiological process. It develops a new but malfunctional microvasculature [37], aiming at facilitating oxygen and nutrients supply, and thereby fuels tumor fast-growth. However, the occurrence of angiogenic activity in GPL, and microvessel morphological changes still remain unclear. In this study, we found that CD34+ microvessels were distributed sparsely in normal gastric mucosa, while their number increased significantly in GPL tissue, supporting the hypothesis that early angiogenesis is existed in GPL rats. Interestingly, in more advanced lesions, gastric mucosa frequently exhibited a higher CD34+ microvessel count. We found more GEDs with a higher number of microvessels than IMs, and more severe GEDs than mild or moderate GEDs. Notably, the most numerous CD34+ microvessels were detected in two model rats with severe GED. The above mentioned phenomena may reveal that gastric precancerosis were frequently heterogeneous in angiogenic behavior, and that a significant higher angiogenic state may imply an increased potential biological attitude towards malignancy, which is in agreement with a previous study [38]. Micromorphologically, the microvessel ultrastructural alterations found in GPL tissue were mainly characterized by dilated vascular lumen, clearly thickened and rough basal lamina, and also by conglobated, degenerated endothelial cell. These characteristics suggest that microvascular abnormalities and hypoxia vasodilation often co-existed in GPL rats. This subsequently induces hypoxia stress together with the activation of hypoxia-inducible factors [39], which stimulate secretion of VEGF and angiogenesis. Hence, angiogenesis may be an adaptive pathobiological response, often accompanying with microvascular abnormalities, triggered by microenvironmental hypoxia in gastric mucosa, aiming at restoring O2 delivery to hypoxic regions. We speculated that chronic inflammation is a prominent inducer, which could result in microvascular injury [40] and also render gastric tissues more hypoxic [41], and therefore drive angiogenesis [42]. (inflammatory infiltration and altered expressions of inflammatory cytokines TNF-α and IL-4 were observed in GPL rats revealed by our previous study [43]). Nonetheless, these were just our preliminary findings, detailed information concerning microcirculation blood flow, inflammation-induced hypoxia and angiogenesis in GPL tissues became our next focus.

Interestingly, WPX administration could rescue microvascular abnormalities and attenuate early angiogenesis in most of the specimens with a concomitant regression of IM and GED lesions. These findings suggested that WPX might possess multi-functions in blocking the GPL aggravation, not only by its anti-angiogenesis ability revealed by a marked drop of MVD level, but also, probably the most important, by ameliorating the microvascular abnormalities and the subsequent microcirculatory dysfunction. HIF-1α and VEGF have been implicated as classic factors controlling multiple proangiogenic processes hijacked by hypoxic tumors, aimed at normalizing blood flow [13]. In this study, we noted that early angiogenesis observed in GPL tissue is paralleled by HIF-1α and VEGF activation. More importantly, WPX could suppress the hypoxia-triggered accumulation of HIF-1α and the VEGF activation, this result supports the hypothesis that HIF-1α and VEGF inhibition plays a beneficial role in WPX-alleviated angiogenesis. While HIF-1α mRNA levels were elevated in GPL tissues, and the number of HIF-1α positive cells was visually reduced after WPX treatment, we archived no statistically significant differences. Given the hypoxia was a heterogeneous concept with uneven oxygen tensions in localized regions [44], spatial maldistribution of HIF-1α activation in GPL tissues may factor in these non-significant differences. Besides, sample size limitation may be another possible contributor.

Angiogenesis is a complex multistep process regulated by compounding factors. It is proposed that ERK/Cyclin D1 could act as specific effectors of VEGF signaling to elicit excessive angiogenesis behavior, and thus facilitated cell proliferation, suggesting a crucial role of the molecules in the initiation and progression of gastric cancer. However, what role the molecules may play in GPL is less clear. In this study, as expected, up-regulated mRNA expressions of ERK1, ERK2 and Cyclin D1 were observed in gastric mucosa from GPL rats as compared to normal mucosa. Our results bring a crucial contribution by evidencing that hyper-angiogenesis observed in GPL is driven, in part, through aberrant activation of ERK-related molecules, suggesting their involvement in the malignant transformation. We were also curious as to whether inhibition of ERK signals is involved in the underlying mechanisms of WPX-mediated attenuation of angiogenesis. Interestingly, after WPX intervention, a decrease in ERK1levels was frequently concurrent with the reduction of CD34+ microvessels. Hence, this ERK mitigating effect might be contributed to the anti-angiogenic activity of WPX against precursor lesions. In addition, no significant decrease in ERK2 levels was observed in WPX-treated rats, which might be due to sample size limitation, or to the speculation that ERK2 might not be the potential therapeutic target for GPL with WPX.

Previously, we have found that H-WPX and M-WPX were more superior to L-WPX in ameliorating gastric precancerosis [45], as well as suppressing cell proliferation and promoting apoptosis [46]. In this study, conversely, L-WPX showed a relatively better anti-GPL activity by attenuating early angiogenesis, and by regulating ERK-related molecules as compared to those of H-WPX and M-WPX. We speculate that different treatment duration (10 weeks in the present study, 4 weeks in the previous studies) might be responsible for the inconsistency. It remains possible that WPX, at low dose, might be more efficient for long-term intervention of GPL when compared with that at high and medium doses. However, due to the small sample size, the speculation need to be further validated in larger scale studies. Our HPLC analysis revealed that Calycosin-7-glucoside, ginsenoside-Rg1, ginsenoside-Rvb1, astragaloside IV, as well as atractylenolide III, II and I might be the potential anti-angiogenic candidates of WPX. Ginsenoside Rg1 has been reported to suppress the vascular neointimal hyperplasia by inhibiting on ERK2 signaling [47]. Ginsenoside Rb1 displayed anti-angiogenesis through suppressing the formation of endothelial tube-like structures [48]. Besides, atractylenolide I displayed a potent inhibitory effect on angiogenesis driven by chronic inflammation in vivo and vitro [49]. Although the aforementioned reports likely support the anti-angiogenesis capacity of WPX, there are some caveats. For instance, there have been conflicting reports regarding the pro-angiogenic role [50, 51] or anti-angiogenic role [52] of astragaloside IV. Thus, much more work remains to be addressed in order to fully exploit anti-angiogenic potential of the compounds in MNNG-induced GPL rats and other GPL models in the future.

Conclusion

In summary, WPX could attenuate the angiogenic response and temper microvascular abnormalities in GPL rats. The anti-angiogenesis property might be related to inhibition on the angiogenesis-associated markers HIF-1α and VEGF, and on the ERK1/Cylin D1 aberrant activation. Additional files 1, 2, 3, 4, 5, 6 and 7.

Abbreviations

ANOVA: 

Analysis of variance

ERK: 

Extracellular signal-regulated kinase

GED: 

Gastric epithelial dysplasia

GPL: 

Gastric precancerous lesions

H&E: 

Hematoxylin and eosin

HID-AB-PAS: 

High-iron diamine- alcian blue-periodic acid schiff

HIF-1α: 

Hypoxia inducible factor-1α

HPLC: 

High performance liquid chromatography

IM: 

Intestinal metaplasia

IOD: 

Integrated optical density.

MNNG: 

N-methyl-N′-nitro-N-nitrosoguanidine

MVD: 

Microvessel density

RT-qPCR: 

Quantitative real-time reverse transcription-polymerase chain reaction

TEM: 

Transmission electron microscope

TNM: 

Tumor node metastasis

VEGF: 

Vascular endothelial growth factor

VIT: 

Vitacoenzyme

WPX: 

Weipixiao

Declarations

Funding

This work was supported by National Natural Science Foundation of China (Nos. 81473620, 81673946, 81774284), and by Science and Technology Developmental Foundation of Affiliated Hospital of Chengdu University of TCM (2016-D-YY-34).

Availability of data and materials

The datasets used and analyzed during the current study available from the corresponding author on reasonable request. All data generated or analyzed during this study are included in this published article.

Authors’ contributions

JHZ and TTC carried out the experiments. HFP and FMY designed the work. ZMZ and WL prepared for WPX and preformed the HPLC analysis. DYG and RY performed histopathological examination. CZ, LHC and YZ provided helpful advice for the manuscript. All authors agree to be accountable for all aspects of the work.

Ethics approval and consent to participate

All procedures relating to animal care and the animal research protocols conformed to the guidelines for the Care and Use of Laboratory Animal, issued by the Ministry of Science and Technology of China. The animal experiments were agreed by the institutional ethical review board of Guangdong Provincial Institute of Traditional Chinese Medicine (Ethic No. GDPITCM111018).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China
(2)
Guangzhou University of Chinese Medicine, Guangzhou, 510405, China
(3)
Guangdong Provincial Institute of Chinese Medicine, Guangzhou, 510095, China
(4)
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, 510530, China

References

  1. Joo YE, Park HK, Myung DS, Baik GH, Shin JE, Seo GS, Kim GH, Kim HU, Kim HY, Cho SI, Kim N. Prevalence and risk factors of atrophic gastritis and intestinal metaplasia: a nationwide multicenter prospective study in Korea. Gut Liver. 2013;7(3):303–10.View ArticlePubMedPubMed CentralGoogle Scholar
  2. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology. 2008;134(4):945–52.View ArticlePubMedGoogle Scholar
  3. Sun SB, Chen ZT, Zheng D, Huang ML, Xu D, Zhang H, Wang P, Wu J. Clinical pathology and recent follow-up study on gastric intraepithelial neoplasia and gastric mucosal lesions. Hepatogastroenterology. 2013;60(127):1597–601.PubMedGoogle Scholar
  4. Srivastava A, Lauwers GY. Gastric epithelial dysplasia: the Western perspective. Dig Liver Dis. 2008;40(8):641–9.View ArticlePubMedGoogle Scholar
  5. Zhang RF, Li JT, He SB, Xiao ZD. Effects of vitacoenzyme on atrophic and intestinal metaplastic lesions in chronic atrophic gastritis--pathologic and histochemical studies of 94 cases. Acad J Sun Yat-Sen Univ Med Sci. 1987;8(2):1–5.Google Scholar
  6. Chen XT, Jiang YH, Chen LH, Li XQ, Kuang ZS, Xie YH, Fang YQ. Effects of Weiyankang plus vitacoenzyme on gastric precancerous lesions and its possible mechanism. Acad J Tradit Chin Med. 2004;22(9):1703–4.Google Scholar
  7. Deng X, Liu ZW, Wu FS, Li LH, Liang J. A clinical study of weining granules in the treatment of gastric precancerous lesions. J Tradit Chin Med. 2012;32(2):164–72.View ArticlePubMedGoogle Scholar
  8. Li HZ, Wang H, Wang GQ, Liu J, Zhao SM, Chen J, Song QW, Gao W, Qi XZ, Gao Q. Treatment of gastric precancerous lesions with Weiansan. World J Gastroenterol. 2006;12(33):5389–92.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Zhang X, Zheng Z, Shin YK, Kim KY, Rha SY, Noh SH, Chung HC, Jeung HC. Angiogenic factor thymidine phosphorylase associates with angiogenesis and lymphangiogenesis in the intestinal-type gastric cancer. Pathology. 2014;46(4):316–24.View ArticlePubMedGoogle Scholar
  10. Gao LM, Wang F, Zheng Y, Fu ZZ, Zheng L, Chen LL. Roles of fibroblast activation protein and hepatocyte growth factor expressions in angiogenesis and metastasis of gastric cancer. Pathol Oncol Res. 2017; https://doi.org/10.1007/s12253-017-0359-3.
  11. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T, Kato Y, Nitta A, Arimoto Y, Kondo Y. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer. 1995;72(2):319–23.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Pinto MP, Owen GI, Retamal I, Garrido M. Angiogenesis inhibitors in early development for gastric cancer. Expert Opin Investig Drugs. 2017;26(9):1007–17.View ArticlePubMedGoogle Scholar
  13. Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS. Targeting hypoxia-inducible factors for antiangiogenic cancer therapy. Trends Cancer. 2017;3(7):529–41.View ArticlePubMedGoogle Scholar
  14. Arany Z, Foo SY, Ma Y, Ruas JL, Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J, Rangwala SM, Baek KH, Rosenzweig A, Spiegelman BM. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature. 2008;451(7181):1008–12.View ArticlePubMedGoogle Scholar
  15. Shin M, Beane TJ, Quillien A, Male I, Zhu LJ, Lawson ND. Vegfa signals through ERK to promote angiogenesis, but not artery differentiation. Development. 2016;143(20):3796–805.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Yang JJ, Cho LY, Ma SH, Ko KP, Shin A, Choi BY, Han DS, Song KS, Kim YS, Chang SH, Shin HR, Kang D, Yoo KY, Park SK. Oncogenic CagA promotes gastric cancer risk via activating ERK signaling pathways: a nested case-control study. PLoS One. 2011;6(6):e21155.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Luo ZY, Wang YY, Zhao ZS, Li B, Chen JF. The expression of TMPRSS4 and Erk1 correlates with metastasis and poor prognosis in Chinese patients with gastric cancer. PLoS One. 2013;8(7):e70311.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Yang D, Fan X, Yin P, Wen Q, Yan F, Yuan S, Liu B, Zhuang G, Liu Z. Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer. BMC Immunol. 2012;13:28.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Modi PK, Komaravelli N, Singh N, Sharma P. Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neurons. Mol Biol Cell. 2012;23(18):3722–30.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Weber JD, Raben DM, Phillips PJ, Baldassare JJ. Sustained activation of extracellular-signal- regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J. 1997;326(Pt 1):61–8.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Guo YL, Rao J, Pan HF, Fang J. Effect of the treatment of Jianpi Huayu Jiedu for patients with chronic atrophic gastritis and its influence on cyclin E protein expression. Chin J Exp Tradit Med Form. 2013;19(11):292–5.Google Scholar
  22. He JJ, Zhang BP, Zhao XY. Clinical efficay of Weipixiao in treating chonic atrophic gastritis. J Guangzhou Univ Tradit Chin Med. 2017;34(6):823–7.Google Scholar
  23. Zhang SL. Clinical efficay of Weipixiao in treating chonic atrophic gastritis (spleen-stomach weakness, syndrome type of TCM): a randomized clinical trial. J Pr Tradit Chin Intern Med. 2017;31(9):12–4.Google Scholar
  24. Yin G, Tang D, Dai J, Liu M, Wu M, Sun YU, Yang Z, Hoffman RM, Li L, Zhang S, Guo X. Combination efficacy of Astragalus membranaceus and Curcuma wenyujin at different stages of tumor progression in an imageable orthotopic nude mouse model of metastatic human ovarian cancer expressing red fluorescent protein. Anticancer Res. 2015;35(6):3193–207.PubMedGoogle Scholar
  25. Wu J, Ke X, Ma N, Wang W, Fu W, Zhang H, Zhao M, Gao X, Hao X, Zhang Z. Formononetin, an active compound of Astragalus membranaceus (Fisch) Bunge, inhibits hypoxia-induced retinal neovascularization via the HIF-1alpha/VEGF signaling pathway. Drug Des Devel Ther. 2016;10:3071–81.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Chen W, Lu Y, Gao M, Wu J, Wang A, Shi R. Anti-angiogenesis effect of essential oil from Curcuma zedoaria in vitro and in vivo. J Ethnopharmacol. 2011;133(1):220–6.View ArticlePubMedGoogle Scholar
  27. Cao HY, Ding RL, Li M, Yang MN, Yang LL, Wu JB, Yang B, Wang J, Luo CL, Wen QL. Danshensu, a major water-soluble component of Salvia miltiorrhiza, enhances the radioresponse for Lewis lung carcinoma xenografts in mice. Oncol Lett. 2017;13(2):605–12.View ArticlePubMedGoogle Scholar
  28. Saito T, Inokuchi K, Takayama S, Sugimura T. Sequential morphological changes in N-methyl-N'-nitro-N-nitrosoguanidine carcinogenesis in the glandular stomach of rats. J Natl Cancer Inst. 1970;44(4):769–83.PubMedGoogle Scholar
  29. Tatematsu M, Aoki T, Inoue T, Mutai M, Furihata C, Ito N. Coefficient induction of pepsinogen 1-decreased pyloric glands and gastric cancers in five different strains of rats treated with N-methyl-N'-nitro-N-nitrosoguanidine. Carcinogenesis. 1988;9(3):495–8.View ArticlePubMedGoogle Scholar
  30. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.View ArticlePubMedGoogle Scholar
  31. Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988;48(13):3554–60.PubMedGoogle Scholar
  32. Dinis-Ribeiro M, Lopes C, da Costa-Pereira A, Guilherme M, Barbosa J, Lomba-Viana H, Silva R, Moreira-Dias L. A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia. J Clin Pathol. 2004;57(2):177–82.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Li D, Bautista MC, Jiang SF, Daryani P, Brackett M, Armstrong MA, Hung YY, Postlethwaite D, Ladabaum U. Risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: a population-based study. Am J Gastroenterol. 2016;111(8):1104–13.View ArticlePubMedGoogle Scholar
  34. Di Gregorio C, Morandi P, Fante R, De Gaetani C. Gastric dysplasia. A follow-up study. Am J Gastroenterol. 1993;88(10):1714–9.PubMedGoogle Scholar
  35. Gonzalez CA, Sanz-Anquela JM, Companioni O, Bonet C, Berdasco M, López C, Mendoza J, Martín-Arranz MD, Rey E, Poves E, Espinosa L, Barrio J, Torres MÁ, Cuatrecasas M, Elizalde I, Bujanda L, Garmendia M, Ferrández Á, Muñoz G, Andreu V, Paules MJ, Lario S, Ramírez MJ, Gisbert JP. Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: results of the Spanish follow-up multicenter study. J Gastroenterol Hepatol. 2016;31(5):953–8.View ArticlePubMedGoogle Scholar
  36. Tarnawski AS, Ahluwalia A, Jones MK. Angiogenesis in gastric mucosa: an important component of gastric erosion and ulcer healing and its impairment in aging. J Gastroenterol Hepatol. 2014;29(Suppl 4):112–23.View ArticlePubMedGoogle Scholar
  37. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417–27.View ArticlePubMedGoogle Scholar
  38. Spina D, Vindigni C, Presenti L, Schürfeld K, Stumpo M, Tosi P. Cell proliferation, cell death, E-cadherin, metalloproteinase expression and angiogenesis in gastric cancer precursors and early cancer of the intestinal type. Int J Oncol. 2001;18(6):1251–8.PubMedGoogle Scholar
  39. Walshe TE, D'Amore PA. The role of hypoxia in vascular injury and repair. Annu Rev Pathol. 2008;3:615–43.View ArticlePubMedGoogle Scholar
  40. Lentsch AB, Ward PA. Regulation of inflammatory vascular damage. J Pathol. 2000;190(3):343–8.View ArticlePubMedGoogle Scholar
  41. Colgan SP, Campbell EL, Kominsky DJ. Hypoxia and mucosal inflammation. Annu Rev Pathol. 2016;11:77–100.View ArticlePubMedPubMed CentralGoogle Scholar
  42. Whiteford JR, De Rossi G, Woodfin A. Mutually supportive mechanisms of inflammation and vascular remodeling. Int Rev Cell Mol Biol. 2016;326:201–78.View ArticlePubMedGoogle Scholar
  43. Li HW, Pan HF, Zhao ZM, Shi YF, Yan Y, Yuan YM, Zeng JH, Lin ZY, Zhao JY. Effect of Weipixiao on plasma tumor necrosis factor alpha and interleukin-4 expression in rats with gastric precancerous lesions. J Guangzhou Univ Tradit Chin Med. 2015;32(2):271–4.Google Scholar
  44. Span PN, Bussink J. Biology of hypoxia. Semin Nucl Med. 2015;45(2):101–9.View ArticlePubMedGoogle Scholar
  45. Pan HF, Zhao ZM, Ren JL, Shi YF. Effect of Weipixiao on gastric epithelial intestinal metaplasia in chronic atrophic gastritis rats. Tradit Chin Drug Res Clin Pharmacol. 2012;23(1):55–7.Google Scholar
  46. Pan HF, Ren JL, Zhao ZM, Liu J. Effect of Weipixiao on cell generation cycle distribution and apoptosis-related gene expression in gastric mucosal epithelial cells of gastric precancerous lesion rats with spleen-deficiency chronic atrophic gastritis. J Guangzhou Univ Tradit Chin Med. 2010;27(5):488–91.Google Scholar
  47. Gao Y, Deng J, Yu XF, Yang DL, Gong QH, Huang XN. Ginsenoside Rg1 inhibits vascular intimal hyperplasia in balloon-injured rat carotid artery by down-regulation of extracellular signal-regulated kinase 2. J Ethnopharmacol. 2011;138(2):472–8.View ArticlePubMedGoogle Scholar
  48. Leung KW, Cheung LW, Pon YL, Wong RN, Mak NK, Fan TP, Au SC, Tombran-Tink J, Wong AS. Ginsenoside Rb1 inhibits tube-like structure formation of endothelial cells by regulating pigment epithelium-derived factor through the oestrogen beta receptor. Br J Pharmacol. 2007;152(2):207–15.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Wang C, Duan H, He L. Inhibitory effect of atractylenolide I on angiogenesis in chronic inflammation in vivo and in vitro. Eur J Pharmacol. 2009;612(1–3):143–52.View ArticlePubMedGoogle Scholar
  50. Wang SG, Xu Y, Chen JD, Yang CH, Chen XH. Astragaloside IV stimulates angiogenesis and increases nitric oxide accumulation via JAK2/STAT3 and ERK1/2 pathway. Molecules. 2013;18(10):12809–19.View ArticlePubMedGoogle Scholar
  51. Wang S, Chen J, Fu Y, Chen X. Promotion of astragaloside IV for EA-hy926 cell proliferation and angiogenic activity via ERK1/2 pathway. J Nanosci Nanotechnol. 2015;15(6):4239–44.View ArticlePubMedGoogle Scholar
  52. Zhang S, Tang D, Zang W, Yin G, Dai J, Sun YU, Yang Z, Hoffman RM, Guo X. Synergistic inhibitory effect of traditional Chinese medicine astragaloside IV and curcumin on tumor growth and angiogenesis in an orthotopic nude-mouse model of human hepatocellular carcinoma. Anticancer Res. 2017;37(2):465–73.View ArticlePubMedGoogle Scholar

Copyright

Advertisement